阿瓦斯汀与雷珠单抗：年龄相关性黄斑变性治疗中的伦理问题。 - Suppr

Suppr

超能文献

Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.

作者信息

Klein Richard M, Klein Ronnie Boriskin

出版信息

Retina. 2007 Nov-Dec;27(9):1163-5. doi: 10.1097/IAE.0b013e31815e9322.

DOI:10.1097/IAE.0b013e31815e9322

PMID:18046218

Abstract

摘要

相似文献

Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.

Retina. 2007 Nov-Dec;27(9):1163-5. doi: 10.1097/IAE.0b013e31815e9322.

Avastin versus Lucentis: ethical issues.

Retina. 2008 Jul-Aug;28(7):1024-5; author reply 1025. doi: 10.1097/IAE.0b013e318176de5f.

Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.

Retina. 2007 Nov-Dec;27(9):1166-7. doi: 10.1097/IAE.0b013e31815ee57e.

Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002.

Intravitreal avastin: the low cost alternative to lucentis?

Am J Ophthalmol. 2006 Jul;142(1):141-3. doi: 10.1016/j.ajo.2006.03.036.

Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?

Acta Ophthalmol Scand. 2007 Feb;85(1):2-4. doi: 10.1111/j.1600-0420.2006.00869.x.

Avastin and new treatments for AMD: where are we?

Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c.

Controversies in the treatment of wet age-related macular degeneration.

Am J Ophthalmol. 2008 May;145(5):937; author reply 938. doi: 10.1016/j.ajo.2008.02.021.

Bevacizumab: a new way of doing business?

Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21.

Comparing ranibizumab with bevacizumab.

Ophthalmology. 2011 Mar;118(3):600-600.e2. doi: 10.1016/j.ophtha.2010.10.027.

引用本文的文献

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1867-72. doi: 10.1007/s00417-014-2886-x. Epub 2014 Dec 13.

Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology.

Mcgill J Med. 2011 Jun;13(1):38.

Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.

Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):819-24. doi: 10.1007/s00417-010-1317-x. Epub 2010 Feb 19.

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Clin Interv Aging. 2009;4:457-61. doi: 10.2147/cia.s8367. Epub 2009 Dec 29.

Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.

Retina. 2007 Nov-Dec;27(9):1163-5. doi: 10.1097/IAE.0b013e31815e9322.

Avastin versus Lucentis: ethical issues.

Retina. 2008 Jul-Aug;28(7):1024-5; author reply 1025. doi: 10.1097/IAE.0b013e318176de5f.

Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.

Retina. 2007 Nov-Dec;27(9):1166-7. doi: 10.1097/IAE.0b013e31815ee57e.

Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002.

Intravitreal avastin: the low cost alternative to lucentis?

Am J Ophthalmol. 2006 Jul;142(1):141-3. doi: 10.1016/j.ajo.2006.03.036.

Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?

Acta Ophthalmol Scand. 2007 Feb;85(1):2-4. doi: 10.1111/j.1600-0420.2006.00869.x.

Avastin and new treatments for AMD: where are we?

Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c.

Controversies in the treatment of wet age-related macular degeneration.

Am J Ophthalmol. 2008 May;145(5):937; author reply 938. doi: 10.1016/j.ajo.2008.02.021.

Bevacizumab: a new way of doing business?

Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21.

Comparing ranibizumab with bevacizumab.

Ophthalmology. 2011 Mar;118(3):600-600.e2. doi: 10.1016/j.ophtha.2010.10.027.

引用本文的文献

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1867-72. doi: 10.1007/s00417-014-2886-x. Epub 2014 Dec 13.

Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology.

Mcgill J Med. 2011 Jun;13(1):38.

Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.

Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):819-24. doi: 10.1007/s00417-010-1317-x. Epub 2010 Feb 19.

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Clin Interv Aging. 2009;4:457-61. doi: 10.2147/cia.s8367. Epub 2009 Dec 29.

Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002.